Mount Sinai researchers studying a type of heart disease known as hypertrophic cardiomyopathy (HCM) have calmed down an artificial intelligence algorithm (AI) to quickly and more specifically identify patients with the condition and signal them as a high risk of more attention.
The algorithm, known as VIZ HCM, had previously been approved by the Food and Drug Administration to detect HCM in electrocardiogram (ECG). The Mount Sinai study, published on April 22 in the magazine Nejm aiassigns numerical chances to the findings of the algorithm.
For example, while the algorithm may have previously said that it is “highlighted as a suspected HCM” or “HCM High Risk”, the Mount Sinai study allows for interpretations such as: “You have about 60 percent probability of having HCM,” says corresponding author Joshua Lampert, MD, MD
As a result, patients who were not previously diagnosed with HCM may be able to better understand their individual risk of illness, leading to faster and more personalized evaluation, along with treatment to prevent complications such as sudden heart death, especially young patients.
This is an important step forward in translating new deep learning algorithms into clinical practice by providing clinicians and patients with more important information. Clinicians can improve their clinical flows, ensuring that patients at a higher risk are located at the top of their clinical business directory using a sorting tool. Patients can be better advised by receiving more personalized information through the calibration of the model that improves the interpretation of models classification ratings. Whether this local model calibration strategy is valid worldwide in other settings remains to be imprinted. This can turn clinical practice because the approach provides important information in a clinically realistic way to facilitate patient care. ”
Dr. Joshua Lampert, Assistant Professor of Medicine (Cardiology, and Datafriend and Digitical Medicine), ICAHN Medical School on Mount Sinai
HCM affects one in 200 people worldwide and is a major reason for a heart transplant. However, many patients do not know that they have the condition until they have symptoms and the disease can already proceed.
Researchers at Mount Sinai ran the HCM VIZ algorithm in about 71,000 patients who had an electrocardiogram between March 7, 2023 and 18 January 2024. The algorithm noted 1,522 as a positive notice for HCM. Researchers reviewed the files and imaging data to confirm which patients had a confirmed HCM diagnosis.
After reviewing confirmed diagnoses, the researchers applied the calibration of the model to the AI tool to evaluate whether the calibrated chance that HCM would have associated with the real chance of patients having the disease. They found that-the calibrated model gave an accurate assessment of the patient’s chance of having HCM.
The use of the model to analyze patients’ ECG results could allow cardiologists to prioritize patients with a higher risk of having them earlier for an appointment and treatment before the symptoms begin or worsen. Doctors will be able to explain the personalized danger to each patient, rather than vaguely stated that an AI model has noted them. This can help young patients deal with and take care of the prevention of adverse effects associated with HCM, such as sudden death or symptoms of the thickened heart muscle, which inhibits blood flow.
“This study provides very necessary detailed to re -think the way we classify. We distort risk and advise patients. In a time of augmented intelligence. We must develop to incorporate new complexity into our approach to patient care” Vivek Reddy, MDArrhythmia Cardiac Services Director for Mount Sinai Health System and Leona M. and Harry B. Helmsley Charitable Trust Frust of Medicine in Cardiac Electrophysiology. “Using hypertrophic cardiomyopathy as an explanatory case of use, we show how we can work realistic new tools even in regulating less common diseases, classifying AI classifications into patients with classification.”
“This study reflects the real application science at its best, proving how we can integrate AI advanced and carefully integrate into real clinical work flows,” says co-sensor author Girish N. Nadkarni, MD, MPH, President of the Windreich Department of Trethial Intellig Plater. Dr. Fishber M. ICAHN Medical School on Mount Sinai. “It’s not just about building a high performance algorithm-to make sure it supports clinical decision-making in a way that improves the full ability of patients and alignment in the way in which care is truly delivered.
The next step is to extend this study and Calibration AI for HCM to additional health systems across the country.
Viz.ai funded this study. Dr. Lampert is a paid adviser for Viz.ai.
Source:
